Table 3 The duration of gametocyte carriage and persistence of gametocytes after treatment with non-ACT, ACT and ACT-PQ in clinical trials in Kenya and Tanzania.
| Â | Duration of gametocyte carriage in days (95% CI) | % still gametocytaemic during follow up (n/N) | |
|---|---|---|---|
| Â | Day 14 | Day 28 | |
Kenya, 2003-2004 | Â | Â | Â |
Non-ACT | 55.6 (28.7-107.7) | 77.8 (28/36) | 48.3 (14/29) |
ACT | 13.4 (10.2-17.5) | 55.6 (50/90) | 11.9 (10/84) |
p-value | < 0.001 | 0.02 | < 0.001 |
Tanzania, 2006 | Â | Â | Â |
ACT | 28.6 (17.0-48.0) | 58.3% (21/36) | 38.9% (14/36) |
ACT-PQ | 6.3 (4.7-8.5) | 4.9%(2/41) | 12.2% (5/41) |
p-value | < 0.001 | < 0.001 | 0.007 |